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Abstract Protein-losing enteropathy (PLE) is a rare compli-
cation of a variety of intestinal disorders characterized by an
excessive loss of proteins into the gastrointestinal tract due to
impaired integrity of the mucosa. The clinical presentation of
patients with PLE is highly variable, depending upon the
underlying cause, but mainly consists of edema due to
hypoproteinemia. While considering PLE, other causes of
hypoproteinemia such as malnutrition, impaired synthesis, or
proteinlossthroughotherorganslikethekidney,liver,orskin,
have to be excluded. The disorders causing PLE can be
divided into those due to protein loss from intestinal
lymphatics, like primary intestinal lymphangiectasia or
congenital heart disease and those with protein loss due to
an inflamed or abnormal mucosal surface. The diagnosis is
confirmed by increased fecal concentrations of alpha-1-
antitrypsin. After PLE is diagnosed, the underlying cause
should be identified by stool cultures, serologic evaluation,
cardiac screening, or radiographic imaging. Treatment of PLE
consists of nutrition state maintenance by using a high protein
diet with supplement of fat-soluble vitamins. In patients with
lymphangiectasia, a low fat with medium chain triglycerides
(MCT)dietshouldbeprescribed.Besidesdietaryadjustments,
appropriate treatment for the underlying etiology is necessary
andsupportivecaretoavoidcomplicationsofedema.PLEisa
rare complication of various diseases, mostly gastrointestinal
or cardiac conditions that result into loss of proteins in the
gastrointestinaltract.Prognosis dependsupontheseverityand
treatment options of the underlying disease.
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Introduction
Protein-losing enteropathy (PLE) is a rare condition
characterized by protein loss through the gastrointestinal
tract, leading to reduced serum protein levels. Incidence
and prevalence are unknown. Hypoproteinemia might be
complicated by edema, ascites, pleural, and cardial effusions.
It can be caused by different disorders, with protein leakage
through either mucosal injury, for example in inflammatory
bowel diseases (IBD) and neoplasms, or through abnormal-
ities of the lymphatic system, as in primary intestinal
lymphangiectasia (PIL), congestive heart failure, or after
Fontan procedure [11, 19, 22, 29]. Treatment of these
underlying causes is the most desirable therapy. Therefore,
every effort must be made to establish a diagnosis in a
patient presenting with PLE.
Pathogenesis
PLE is not a single disease but a complication of a variety
of intestinal disorders, in which the membranes lining the
gastro-intestinal tract fail to hold back the proteins of tissue
fluids. Although enteropathy is defined as an intestinal
disease, the term PLE is more liberally used including loss
from the esophagus and stomach as well. The serum protein
level reflects the balance between synthesis, metabolism
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the gastrointestinal tract compared to synthesis. The most
affected protein is albumin, because of its slow turnover
rate in steady state and therefore hypoproteinemia in PLE is
usually detected as hypoalbuminemia. In order to diagnose
PLE, other possible causes of hypoalbuminemia as stated in
Table 1 have to be excluded.
Albumin is a water-soluble molecule that maintains
plasma oncotic pressure and functions as a transport protein
for hormones, fatty acids, ions, and bilirubin. In the steady
state situation, the total amount of albumin broken down
daily (6–10%) is equal to the amount synthesized [23, 31].
In healthy individuals, protein loss through the gut does not
significantly contribute to the albumin catabolism. Enteric
loss of albumin is only 10% of the normal turnover; but in
patients with PLE, the enteric albumin loss can be increased
up to 60% [27]. In these patients, the albumin synthesis is
increased with 24%. The serum albumin levels remain low
due to excessive losses. This suggests that although
synthesis is expanded, the liver is not able to compensate
completely for the extreme losses [31]. Not only albumin,
but also other proteins with a slow turn-over rate such as
immunoglobulins and ceruloplasmin are affected, this is
contrary to levels of proteins with shorter half lives, such
as, IgE, clotting factors, pre-albumin, and transferrin, which
are almost preserved in the normal range [27].
When to consider PLE
PLE should be considered in patients with hypoalbuminemia
andedemainwhomotherpossiblecausesasstatedabovehave
been excluded. The clinical manifestations are determinated
by the underlying disorder. These will be discussed in the
chapter “causes”.
Main laboratory findings are reduced serum concentration
of albumin, gammaglobulins, and ceruloplasmin. Diminished
oncotic pressure due to hypoalbuminemia may lead not only
to edema, but also to ascites and pleural or pericardial
effusions. PLE can also be associated with fat malabsorption
and deficiencies of fat-soluble vitamins due to small bowel
involvement.
Causes of PLE
There are two different mechanisms through which an
increase in intestinal plasma protein loss can occur: (1)
abnormalities of the lymphatic system, resulting in leakage
of protein-rich lymph and (2) mucosal injury, with
increased mucosal permeability (Table 2).
Abnormality of the lymphatic system
Intestinal lymphangiectasia is an uncommon disorder and
an important cause of protein-losing enteropathy. It was
first reported in 1961 by Waldmann et al. [29]. The major
symptoms were edema and hypoproteinemia, low serum
albumin and gammaglobulin levels. Biopsies of the small
intestine showed variable degrees of dilatation of lymph
vessels in the mucosa and submucosa. The authors
introduced the term “intestinal lymphangiectasia” for this
condition.
Intestinal lymphangiectasia is characterized by diffuse or
local dilatation of the enteric lymphatics, which can be
located in the mucosa, submucosa, or subserosa. Because of
stasis and eventually rupture of the lymph vessels,
lymphatic fluid, rich in albumin and other proteins, leaks
into the gastrointestinal tract [22]. Besides excessive protein
loss, there is also malabsorption of both chylomicrons and
fat-soluble vitamins. These structural lymphatic abnormalities
can occur as congenital malformation, called PIL, or as
acquired defects, secondary to other diseases.
PIL is generally diagnosed before 3 years of age, equally
affecting boys and girls. The prevalence of PIL is unknown.
Patients with PIL often present with pitting limb edema and
gastrointestinal symptoms like intermittent diarrhea, nausea,
or vomiting. Other major features are lymphopenia, hypo-
albuminemia, and hypogammaglobulinaemia due to lymph
leakage from the ruptured lymph vessels.
In secondary lymphangiectasia, the dilatation of the
lymphatics is caused by obstruction of the vessels or an
elevated lymph pressure, secondary to elevated venous
pressure. Obstruction can be seen in patients with IBD,
sarcoidosis, or lymphoma, whereas elevated lymph pressure
is present in patients with congestive heart failure or
constrictive pericarditis [9]. Syndromes that are also
associated with intestinal lymphangiectasia include von
Recklinghausen, Turner, Noonan, Klippel-Trenaunay, and
Hennekam. Another group of patients, in which secondary
lymphangiectasia is observed, are patients who have
Table 1 Causes of hypoalbuminemia
Causes of hypoalbuminemia
1. Decreased production
Protein malnutrition
Defective synthesis
2. Increased loss
Protein-losing enteropathy
Nephrotic syndrome
Excessive burns
3. Redistribution
Inflammation of vasculature (e.g., sepsis)
Hemodilution
1180 Eur J Pediatr (2010) 169:1179–1185undergone a Fontan operation. This is a surgical procedure
used in children with complex congenital heart diseases
with a single effective ventricle either due to a defect of the
heart valves (tricuspid atresia or pulmonary atresia) or
underdevelopment of the left side of the heart (hypoplastic
left heart syndrome). PLE is an uncommon but life-
threatening complication of the Fontan operation that
occurs in 4–13% of the patients and associated with a very
high mortality and a 5-year survival rate of 46–50% [11,
19]. The patholophysiological mechanism of PLE after
Fontan surgery is not completely well understood. Elevated
systemic venous pressure and subsequent dilation of
lymphatics and protein loss is thought to be an important
factor [19]. Ostrow et al. [21] investigated other possible
pathophysiological mechanisms of PLE after Fontan surgery
and found abnormal abdominal vascular resistance and
elevated levels of inflammatory markers. They suggested that
diminished flow in the mesenteric artery in combination with
elevated venous pressure could lead to impaired mesenteric
perfusion, modulation of the intestinal cell membrane, and
protein leakage. The inflammation may additionally result in
changes in the endothelial function.
Mucosal injury
Inflammatory and ulcerative diseases
A variety of conditions can cause mucosal erosions, the
most common being IBD like Crohn’s disease and
ulcerative colitis. The mechanism of protein loss is
probably related to enhanced leakage of protein-rich fluids
across the eroded mucosa. In addition to mucosal cell
injury, IBD can also lead to secondary lymphangiectasia,
with subsequently leakage of protein-rich lymph through
the gut [3]. Although not extensively studied, certain
enteric infections can also damage the intestinal mucosal
leading to excessive protein loss. These losses can be
severe during infections with bacteria-like Salmonella and
Shigella [4], but has also been reported in infections with
Giardia lamblia [26]. Recently, the rare case of Rotavirus
Mucosal injury
1. Inflammatory and ulcerative diseases
Inflammatory bowel disease: Crohn’s disease/ulcerative colitis
Infections
Bacterial: Salmonella, Shigella, Campylobacter, Clostridium difficile
Parasitic: Giardia liamblia
Viral: Rotavirus
Gastrointestinal malignancies:
Oesophageal, gastric, colonic adenocarcinomas
Lymphoma
Kaposi’s sarcoma
NSAID enteropathy
Graft vs Host disease
Necrotizing enterocolitis
Ulcerative ileitis
2. Non-ulcerative diseases
Hypertrophic gastropathies (Ménétrier’s disease)
Eosinophilic gastroenteritis
Food induced enteropathy
Coeliac disease
Tropical sprue
Small intestinal bacterial overgrowth
Vasculitic disorders: SLE, HSP
Lymphatic abnormalities
1. Primary intestinal lymphangiectasia (PIL)
2. Secondary intestinal lymphangiectasia
Obstructive: Crohn, sarcoidosis, lymphoma
Elevated lymph pressure: congestive heart failure, constrictive pericarditis
Syndromal: Turner, Noonan, Hennekam, Klippel-Trenaunay, v.Recklinghausen after Fontan procedure
Table 2 Causes of
protein-losing enteropathy
SLE systemic lupus
erythematosus, HSP Henoch
Schönlein purpura
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has been reported [15]. In children with hemolytic and
uremic syndrome and prodromal diarrhea, significant
hypoalbuminemia can also be found [13].
Non-ulcerative diseases
A number of conditions can alter the integrity of the mucosal
cell, followed by enhanced permeability and subsequent
protein leakage into the lumen. One of the non-ulcerative
gastrointestinal disorders in childhood PLE is Ménétrier’s
disease, also known as giant hypertrophic gastropathy. This
raredisorderischaracterizedbygiantrugalfoldsinthestomach
and an increase in intracellular permeability and wider tight
junctions between cells that result into protein loss. Patients
usually present with non-specific gastrointestinal complaints,
such as nausea, vomiting, anorexia, weight loss, and general-
ized edema. One of the major causes of Ménétrier’s disease is
the cytomegalovirus; however, an association with Helico-
bacter pylori has also been described [5, 8, 18]. In children,
the disease is usually self-limited without recurrence or
sequelae, unlike adults in whom the disease is chronic.
In children with milk and soy sensitivity or allergic
esinophilic gastroenteritis (AEG), hypoalbuminemia can be
detected. Biopsies taken from the mucosa from these patients
shows marked esinophilic infiltration of the gastrointestinal
tissues with increased mast cells. It is suggested that mast cell
infiltration is related to increased intestinal permeability and
protein loss in patients with AEG [6, 17, 20].
In celiac disease, protein loss is a consequence of loss of
villi and surface epithelium, which facilitates the leakage of
plasma proteins between the cells.
Excessive protein loss is also associated with vascular
disorders like systemic lupus erythematosus (SLE) or Henoch
Schönlein Purpura, either at diagnosis or during the course of
these diseases. In these disorders, hypoalbuminemia is caused
by increased capillary permeability.
How to diagnose PLE
In most patients, the diagnosis will be derived from history,
physicalexamination,andclinicalmanifestations.However,if
necessary, protein-losing enteropathy can be established by
the detection of alpha-1-antitrypsin in a stool sample, or with
the use of functional imaging.
Alpha-1-antritrypsin
PLE can be detected by increased alpha-1-antitrypsin concen-
trationinacollectedstoolsample[25]. It is a sensitive marker
because alpha-1-antitrypsin is of similar size to albumin
(50 kDa), not actively secreted, not absorbed and, with
the exception of the stomach, not degraded. The
measurement of alpha-1-antitrypsin clearance requires
both a blood sample to determine alpha-1-antitrypsin
plasma level and a 24-h stool collection to determine
stool volume and stool alpha-1-antitrypsin level. Normal
alpha-1-antitrypsin clearance is <24 ml/24 h, this
increases to >56 in patients with diarrhea [22]. When
alpha-1-antitrypsin clearance is above normal levels, the
diagnose PLE can be made. However, the detection of
alpha-1 antitrypsin does not show the site of protein loss
in the intestine. Furthermore, it will not show a positive
result when the stomach is the place of leakage [28].
Functional imaging
An important advantage of functional imaging is the
possibility to localize the site of the protein loss. Several
radiopharmaceuticals have been used for the detection of
protein leakage. In-111-transferin, Tc-99m human immuno-
globulin, Tc-99m dextran , Tc-99m human serum albumin
(Tc-99m HSA), and Tc-99m methylene diphosphonate (Tc-
99m MDP) are some of the more prominent tracers
investigated, the latter two being frequently used.
Several studies have reported that Tc-99m HSA is able
to diagnose PLE. Halaby et al. [14] showed a positive scan
in 12 out of 18 patients with PLE. Chiu et al. [7] reported
an increased sensitivity of Tc-99m HSA of 96%, and a
specificity of 100% in 26 patients. No adverse reactions to
the tracer were described. Functional imaging with Tc-99m
serum albumin has been able to identify the region of
protein leakage [24, 30].
After PLE has been diagnosed, a search for the underlying
cause shouldbe performed. Bacterial, viral, and parasitic stool
cultures can be used to search for infectious diseases.
Serologic evaluation will reveal immune disorders and ECG
or echocardiography might be necessary to determine the
cardiac condition. To localize the intestinal area of
involvement, radiographic studies like CT or MRI can
be used. Endoscopy can detect characteristic mucosal
alterations like giant gastric folds in Ménétrier’s disease.
In patients with suspected lymphangiectasia, a high-fat
meal before endoscopy is recommended because this
increases enteric lymph flow and elevates lymphatic
pressures leading to more prominent lymphatics with
increased leakage of lymph into the bowel lumen, seen
as white spots on the mucosa (Fig. 1). During endoscopy,
biopsies are obtained to confirm histological features.
Wireless capsule endoscopy identifies abnormalities of the
small intestinal intestine in a non-invasive way without
using ionizing radiation. It can safely be performed in
children >1.5 years old [12]. The approach to the patient
with suspected protein-losing gastroenteropathy is out-
lined in Figure 2.
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The actual treatment of PLE should consist of main-
tenance of nutritional status and treatment of the under-
lying disease.
Maintenance of nutritional status
In all patients with PLE, a high-protein diet is recom-
mended. Normal protein requirements are age dependent,
v a r y i n gb e t w e e n1 . 5g / k g / d a yf o ran e w b o r na n d0 . 6 6g /
kg/day at the age of 18 years, in PLE this amount may
increase to 1.5–3.0 g/kg/day to achieve a positive protein
balance [1]. This increased protein intake can be
accomplished through dietary changes, but sometimes
protein supplements are necessary. Along with the
dietary treatment, water-soluble forms of fat-soluble
vitamins should be supplemented. In a number of
diseases, a specific diet is indicated such as gluten-free
diet in celiac disease or hypoallergenic diets in patients
with allergic gastroenteropathy.
Fig. 1 Endoscopic image of a child with intestinal lymphangiectasia
after a high-fat meal showed scattered white spots on the mucosa of
the duodenum
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Fig. 2 Work up in children with
hypoalbuminemia and edema
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with high protein and low fat substituted with MCT. Exclusion
of long chain fatty acids (LCT) reduces lymphatic flow and
pressure, and thus prevents rupture of malformed lymphatics,
while MCT are directly absorbed into the portal venous
circulation and bypass the enteric lymphatics. MCT oil should
not completely replace all dietary fats, as this would result in a
deficiency of essential fatty acids. If a MCT diet is necessary,
the essential fatty acids should be included in the regimen [2,
10]. In case of poor response to this treatment, partial or total
parenteral nutrition can be considered. To date, few publica-
tions have suggested that octreotide treatment in patients with
PIL was associated with a decrease in enteral protein loss in
clinical improvement. The mechanisms of action of these
somatostatin analog remains unclear [10].
Treatment of the underlying disease
In patients with PLE associated with acquired lymphangiecta-
sia, underlying causes should be treated in order to decrease
intestinal protein loss. When cardiac diseases cause PLE,
proteinlosscanbeimprovedaftersurgeryormedicaltreatment.
In patients who underwent a Fontan procedure, PLE is
sometimes reversible after surgical intervention (Baffle fenes-
tration), or after the use of corticosteroids or heparin [11]. In
patients with Ménétrier’s disease ussually only supportive
care is required, but treatment with gangciclovir or, in case of
gastric inflammation, H2 receptor blockers or proton pump
inhibitors can be necessary in complicated cases [18]. In
Whipple’s disease, infections with H. pylori or other bacteria,
the pathogens should be treated with appropriate antibiotics.
When symptoms of inflammatory diseases are present as in
IBD, graft-versus-host disease, or SLE, corticosteroids have
been demonstrated to improve the course of PLE [16].
When medical treatment of PLE has failed, surgical
resection remains an option, especially when protein loss is
due to hypertrophic gastritis, inflammatory bowel diseases
or neoplasms limited to isolated segments of the bowel.
Most other PLEs are too widely distributed for resection
[16].
In acute situations infusions of albumin can be used to
increase plasma oncotic pressure. Albumin infusions are
effective only in the short-term and can be used only as
bridging intervention. Supportive care with stockings and
limb elevation is very useful to avoid complications from
peripheral edema. The skin should be protected and skin
infections treated early.
Prognosis
Very little is known about morbidity and mortality of PLE.
It depends on the underlying diseases and the availability of
proper treatment. Only in the Fontan studies, as mentioned
above, mortality rates are as high as 46% [19].
Conclusion
Protein-losing enteropathy is characterized by loss of proteins
into the gastrointestinal tract and develops as a rare compli-
cation of various diseases, mostly gastrointestinal or cardiac
conditions. The resulting hypoproteinemia can lead to edema,
sometimes ascites, and pleural or cardiac effusions. Alpha-1
antitrypsin clearance and scintigraphic techniques are useful
tools to measure protein loss and localize the site of protein
leakage.Disordersthatcause PLEcanbeidentifiedbyclinical
history, laboratory tests, and radiographic studies. The
prognosis of PLE is unknown and mainly depends upon the
underlying disease. Treatment of PLE mainly consists of
appropriate treatment of the underlying cause and mainte-
nance of the nutritional state with dietary modification.
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